About
Our Mission
Leadership
Partners
Our Technologies
TALEN® Technology
Gene Editing
PulseAgile Technology
Patents
Pipeline
Products
Clinical Indications
Manufacturing
Investors
Press Releases
Corporate presentation & ESG report
Scientific Presentations
Scientific Publications
Events and Webcasts
2021 Cellectis Innovation Days
Stock Information
Corporate Governance
Governance Documents
Board of Directors & Committee Members
Shareholders Meeting
SEC Filings
Contact
IR Inquiries
Email Alerts
Investor FAQ
Careers
Our Culture
Job Opportunities
Contact us
fr
Scientific Presentations
Press releases
Corporate presentation
Scientific Presentations
Scientific Publications
Events and webcasts
Stock information
SEC filings
Financial Statements
Regulated information
Voting Rights & Share Capital
ATM Program
General meetings
Governance
The board and committee members
Corporate governance documents
FAQ
IR Inquiry
All
2024
2023
2022
2021
12
Dec 2023
10:48 E.S.T.
Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) - ASH 2023 - Poster Presentation
Download the PDF file
12
Dec 2023
10:44 E.S.T.
Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) - ASH 2023 - Poster Presentation
Download the PDF file
05
Nov 2023
15:16 E.S.T.
TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer - SITC 2023 - Poster Presentation
Download the PDF file
27
Oct 2023
04:41 E.S.T.
Comprehensive Analysis of the Editing Window of TALE Base Editors - ESGCT 2023 - Poster Presentation
Download the PDF file
27
Oct 2023
04:38 E.S.T.
Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy - ESGCT 2023 - Poster presentation
Download the PDF file
27
Oct 2023
04:34 E.S.T.
Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS - ESGCT 2023 - Poster Presentation
Download the PDF file
22
Sep 2023
09:06 E.S.T.
TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors - CICON 2023 - Poster Presentation
Download the PDF file
08
Jun 2023
04:21 E.S.T.
Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) - EHA 2023 - Poster Presentation
Download the PDF file
05
Jun 2023
06:53 E.S.T.
UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies - ISCT 2023 - Oral Presentation
Download the PDF file
05
Jun 2023
03:29 E.S.T.
Comprehensive Analysis of the Editing Window of TALE Base Editors ISCT 2023 - Poster Presentation
Download the PDF file
1
2
Next